MYMX - Mymetics Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
0.0545
-0.0005 (-1.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.0550
Open0.0627
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0481 - 0.0627
52 Week Range0.0210 - 0.0650
Volume397,282
Avg. Volume154,975
Market Cap16.54M
Beta (5Y Monthly)-0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.0160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    Mymetics Reports Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergy Immunotherapy

    Second-generation Allergen Immunotherapy with COP-virosomes, based on Anergis Contiguous Overlapping Peptides (COP) linked to Mymetics' virosomes were tested by Stallergenes Greer in a therapeutic model of birch pollen allergy. The results showed that a treatment with COP-virosomes was able to cure allergic asthma in birch pollen sensitized mice. EPALINGES, SWITZERLAND / ACCESSWIRE / May 28, 2020 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life threatening and life disabling diseases, announced today that Stallergenes Greer, a worldwide leader in allergen immunotherapy (AIT) and Anergis, a leader in ultra-fast AIT research and development, reported the results of a joint research study evaluating the effects of the second generation Contiguous Overlapping Peptides (COP) allergen immunotherapy in a therapeutic model of birch allergy, with the aim of shortening the AIT administration schemes.

  • ACCESSWIRE

    Mymetics and Baylor College of Medicine start Research Collaboration for Virosome-based Covid-19 Vaccines

    Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective ...

  • ACCESSWIRE

    Mymetics Announces New Study to Predict Efficacy of Second- Generation COP Allergy Immunotherpy with Virosomes

    EPALINGES, SWITZERLAND / ACCESSWIRE / October 17, 2019 / Mymetics Corporation (MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life threatening and life disabling diseases, announced today that Stallergenes Greer, a worldwide leader in Allergen Immunotherapy (AIT), and Anergis, a leader in ultra-fast AIT research and development based on Contiguous Overlapping Peptides (COP), announced the start of a new research study to evaluate the effects of the second generation virosome- based COP allergen immunotherapy in a therapeutic model of birch allergy in mice. The aim is to shorten the AIT administration scheme.